Summary
CJC-1295 without DAC, also called Modified GRF (1-29), is sermorelin with four amino acid substitutions that make it more resistant to breakdown. It lasts longer than sermorelin but far shorter than the DAC version. Published human data specific to this molecule are scarce.
Structure
GRF(1-29) with D-Ala2, Gln8, Ala15 and Leu27 substitutions that resist enzymatic breakdown. No albumin-binding group.
How it works
Stimulates the pituitary GHRH receptor like sermorelin. The D-Ala2 substitution blocks DPP-4 cleavage, which is the main way native GHRH is inactivated.
Research use cases
Areas where CJC-1295 (no DAC) has been studied. Inclusion here does not mean it works for that purpose.
- Short-acting GH pulse stimulation
- Combination studies with ghrelin-receptor agonists
What the research found
Design origin
The tetrasubstituted GRF backbone was developed as the peptide portion of CJC-1295. Its standalone pharmacology has mostly been characterized in animals.1
Safety and open questions
No dedicated controlled human studies.
Regulatory status
Not approved. Sold for research use.
Status was accurate when this page was last reviewed on October 26, 2026. Regulations change; check with the relevant authority before relying on it.
CJC-1295 (no DAC): common questions
Why is it paired with ipamorelin?
GHRH analogs and ghrelin-receptor agonists act on different pituitary receptors, and in studies of related compounds the combination released more GH than either alone. Data on this exact pairing in people are limited.
Is CJC-1295 (no DAC) approved for human use?
Not approved. Sold for research use.
References
- Jetté L, Léger R, Thibaudeau K, et al. (2005). Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology.
Links open a PubMed search for the exact title, or the original source where one is given.